In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on ...
3d
Hosted on MSNWilliam Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical ...
On Thursday, William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug ...
As of 3:35:18 PM EST. Market Open.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results